IRIS
MARRONE, Aldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.962
EU - Europa 4.167
AS - Asia 1.097
AF - Africa 9
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 10.250
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.931
IE - Irlanda 1.363
UA - Ucraina 687
GB - Regno Unito 564
IT - Italia 535
CN - Cina 501
DE - Germania 343
SG - Singapore 342
SE - Svezia 237
FI - Finlandia 177
TR - Turchia 177
GR - Grecia 127
FR - Francia 60
KR - Corea 32
CA - Canada 27
BE - Belgio 25
IN - India 12
NL - Olanda 12
CZ - Repubblica Ceca 10
RU - Federazione Russa 8
HK - Hong Kong 7
ID - Indonesia 7
IR - Iran 7
EU - Europa 6
EG - Egitto 5
RO - Romania 5
JP - Giappone 4
AR - Argentina 3
CH - Svizzera 3
HR - Croazia 3
MX - Messico 3
AT - Austria 2
CL - Cile 2
LT - Lituania 2
PE - Perù 2
TW - Taiwan 2
UG - Uganda 2
VN - Vietnam 2
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
BR - Brasile 1
BW - Botswana 1
HU - Ungheria 1
JM - Giamaica 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
Totale 10.250
Salva come PNG Salva come JPEG
Città #
Dublin 1.357
Jacksonville 1.045
Chandler 713
Santa Clara 709
New York 256
Singapore 224
Princeton 210
Roxbury 158
Woodbridge 139
Ann Arbor 126
Boardman 121
Cambridge 116
Bremen 110
Wilmington 104
Medford 100
Caserta 64
Beijing 57
Jinan 57
San Mateo 53
Shenyang 52
Nanjing 50
Ashburn 49
Des Moines 43
Naples 42
Mountain View 41
Düsseldorf 33
Seoul 32
Zhengzhou 29
Brussels 25
Nanchang 25
Munich 22
Napoli 22
Houston 21
Norwalk 19
Washington 19
Changsha 17
Guangzhou 17
Haikou 17
Hangzhou 17
Los Angeles 17
Hebei 15
Helsinki 14
Ningbo 14
Auburn Hills 13
Lanzhou 13
Ottawa 12
Shanghai 12
Tianjin 12
Taiyuan 11
Taizhou 11
Kunming 10
Seattle 10
Jiaxing 9
Dearborn 8
Marano Di Napoli 8
Amsterdam 7
Hong Kong 7
Istanbul 7
London 7
Rome 7
Toronto 7
Milan 6
Guastalla 5
Marigliano 5
Portici 5
Redwood City 5
Rossano 5
Zanjan 5
Andover 4
Atlanta 4
Cesa 4
Changchun 4
Hefei 4
Hyderabad 4
Lappeenranta 4
Padova 4
Sacramento 4
Venice 4
Avellino 3
Aversa 3
Brno 3
Elora 3
Frankfurt am Main 3
Frattamaggiore 3
Fuzhou 3
Palermo 3
Paris 3
Perugia 3
San Francisco 3
San Giuseppe Vesuviano 3
Tokyo 3
Zurich 3
Aosta 2
Athens 2
Bari 2
Barlassina 2
Bergamo 2
Bologna 2
Bonea 2
Brdo 2
Totale 6.676
Salva come PNG Salva come JPEG
Nome #
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 117
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 104
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 95
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 94
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 91
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 87
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 83
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 78
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 77
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 74
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 74
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 73
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 73
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C 72
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 70
Chronic HCV infection and neurological and psychiatric disorders: an overview. 69
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 69
Activity of aminoglycosides against phagocytosed bacteria 68
Espressione dell'infezione da citomegalovirus (CMV) in pazienti cardiotrapiantati 68
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 67
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 67
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 66
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 66
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 65
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 64
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 64
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 64
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study 63
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 63
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 62
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 62
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 62
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 62
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 62
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 62
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 61
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 61
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 61
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 61
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 61
Complicanze infettive in pazienti sottoposti a trapianto di cuore. 61
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection 60
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 60
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 59
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 59
Ricerca del sangue occulto nelle feci con Hemoquant: prevenzione e diagnostica. 59
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 59
Eighteen months lamivudine prophylaxis of occult HBV infection (OBI) reactivation and standard therapy of overt chronic infection in oncohematologic immunosuppressed patients: an interim analysis 59
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 58
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 58
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. 58
Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome 58
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 58
Interferon plus lamivudine treatment in young patients with chronic active B and C hepatitis 58
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 58
Severe diarrhea occurring during alpha-interferon treatment for chronic hepatitis C is associated with serologic markers of celiac disease 58
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 57
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 57
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 57
Hepatitis C virus infection in Italy: a multicentric sero-epidemiological study. (A report from the HCV study group of the Italian Association for the study of the liver) 56
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 56
HCV-related steatosis and risk of atherosclerosis 56
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 56
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 56
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 56
Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology? 55
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 55
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 55
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 55
Suscettibilità antibiotica di enterococchi recentemente isolati. 55
Efficacia del trattamento con interferone ricombinante e linfoblastoide in pazienti con epatite cronica da HCV. 55
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 54
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 54
SEQUENTIAL ANALYSIS OF HEPATITIS B VIRUS CORE PROMOTER AND PRECORE REGIONS IN CANCER SURVIVOR PATIENTS WITH CHRONIC HEPATITIS B BEFORE, DURING AND AFTER INTERFERON TREATMENT 54
Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant 54
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 53
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 53
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore 53
Infezioni respiratorie da Branhamella Catarralis in pazienti sottoposti a trapianto di cuore 53
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 53
Chronic HCV infection is a risk factor of ischemic stroke 53
Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection 52
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia 52
Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior 52
Baseline HBV-DNA level is an important predictor of response to interferon in children with chronic hepatitis B 52
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 52
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 52
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 51
Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study 51
The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology 51
Efficacia e tollerabilità dell'alfa interferone (IFN) nell'epatite cronica post-trasfusionale (PTCH) da HCV: dati preliminari di soggetti precedentemente sottoposti a cardiochirurgia. 51
Studio dellla suscettibilità antibiotica di stafilococchi responsabili di infezioni nosocomiali 51
Clearance of HBsAg and HBV-DNA after lamivudine (LAM) or entecavir (ET) rescue therapy in oncohaematological patients with hepatitis B virus (HBV) reactivation: complete recovery of four cases 51
Studio prospettico controllato del trattamento prednisone interferone in pazienti pediatrici con epatite cronica da HBV 51
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 51
Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals 50
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment. Predictive Factors and Role of Epigenetics 50
Efficacia e sicurezza dell’entecavir nel controllo dell’infezione da HBV nel paziente oncoematologico 49
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 49
The epidemiology of hepatitis delta infection in Italy 48
Totale 6.139
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.508
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.508
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020433 0 0 0 0 0 0 229 39 59 32 62 12
2020/20211.682 120 15 173 95 435 16 205 159 8 214 175 67
2021/20221.284 59 3 8 15 435 14 11 35 64 124 102 414
2022/20232.682 235 45 38 216 326 221 4 174 1.276 27 64 56
2023/20241.207 95 33 61 97 372 262 17 34 4 14 77 141
2024/20251.055 27 42 33 87 502 357 7 0 0 0 0 0
Totale 10.637